Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia

被引：3
|
作者：
Haddad, Fadi [1 ]
Kantarjian, Hagop [1 ]
Issa, Ghayas C. [1 ]
Jabbour, Elias [1 ]
Sasaki, Koji [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 07期
关键词：
PERIPHERAL NEUROPATHY; IMATINIB; DASATINIB; THERAPY; EDEMA;
D O I：
10.1080/10428194.2022.2045599
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1714 / 1717
页数：4
相关论文
共 50 条
  • [1] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [2] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Malik, Sara
    Hassan, Shahzeb
    Eskazan, Ahmet Emre
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
  • [3] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [4] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
  • [5] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
    Erbilgin, Yucel
    Eskazan, Ahmet Emre
    Ng, Ozden Hatirnaz
    Salihoglu, Ayse
    Elverdi, Tugrul
    Firtina, Sinem
    Tasar, Orcun
    Mercan, Sevcan
    Sisko, Sinem
    Khodzhaev, Khusan
    Ongoren, Seniz
    Ar, Muhlis Cem
    Baslar, Zafer
    Soysal, Teoman
    Sayitoglu, Muge
    Ozbek, Ugur
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
  • [6] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Press, Richard D.
    Kamel-Reid, Suzanne
    Ang, Daphne
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
  • [7] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Dakota Gustafson
    Jason E. Fish
    Jeffrey H. Lipton
    Nazanin Aghel
    [J]. Current Hematologic Malignancy Reports, 2020, 15 : 20 - 30
  • [8] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
  • [9] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Eiring, A. M.
    Khorashad, J. S.
    Anderson, D. J.
    Yu, F.
    Redwine, H. M.
    Mason, C. C.
    Reynolds, K. R.
    Clair, P. M.
    Gantz, K. C.
    Zhang, T. Y.
    Pomicter, A. D.
    Kraft, I. L.
    Bowler, A. D.
    Johnson, K.
    Mac Partlin, M.
    O'Hare, T.
    Deininger, M. W.
    [J]. LEUKEMIA, 2015, 29 (12) : 2328 - 2337
  • [10] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    A M Eiring
    J S Khorashad
    D J Anderson
    F Yu
    H M Redwine
    C C Mason
    K R Reynolds
    P M Clair
    K C Gantz
    T Y Zhang
    A D Pomicter
    I L Kraft
    A D Bowler
    K Johnson
    M Mac Partlin
    T O'Hare
    M W Deininger
    [J]. Leukemia, 2015, 29 : 2328 - 2337
12345